



Masterclass on Tumor Biomarkers

October 19-20, 2017 Radisson Blu Park Hotel Athens



Organized by HELLENIC SOCIETY OF MOLECULAR THERAPEUTIC TARGETING OF CANCER

Scientific Program





Masterclass on Tumor Biomarkers 2017

Thursday October 19th, 2017

08:55-09:00	Welcome address	
09:00-10:10	Session 1: Tissue Tumor Biomarkers	
09:00-09:20	Molecular and immunohistochemical characterization of solid tumors	A. Kotsakis
09:20-09:40	Biomarkers in Breast cancer	E. Lagoudaki
09:40-10:00	Emerging role of biomarkers in NSCLC	E. Kourea
10:00-10:10	Discussion	T. Bilidas
10:10-11:00	Session 2: Circulating Tumor Cells: Detection and Molecular characterization	
10:10-10:30	Methods for CTCs detection (molecular & other)	A. Strati
10:30-10:50	Phenotypic heterogeneity and characterization	G. Kallergi
10:50-11:00	Discussion	
11:00-11:20	Coffee Break	
11:20-13:40	Session 3: biomarkers in immuno-oncology	
11:20-11:50	PD-L1 as a biomarker for the treatment with immune checkpoint inhibitors	A. Koutsopoulos
11:50-12:20	Immune checkpoint inhibitors beyond PD-1/PD-L1 axis	S. Kokkali
12:20-12:50	Prognostic and predictive value of TILs	P. Foukas
12:50-13:20	Updated data for the detection of Pd-L1 in liquid biopsies	E. Lianidou
13:20-13:40	Discussion	
13:40-14:25	Lunch	
14:25-16:05	Lecture session (I)	
14:25-14:55	Biomarkers of inflammation	I. Pateras
14:55-15:25	MLL3 as a potential biomarker for treatment selection	Th. Rampias
15:25-15:55	CRC: what's next after RAS family mutations	A. Pintzas
15:55-16:05	Discussion	
16:05-17:15	Lecture Session (II)	
16:05-16:35	Exosomes as a potential source of several biomarkers	E. K. Vetsika
16:35-17:05	CDK 4/6 inhibitors. A new therapeutic approach for the treatment of breast cancer	E. Kontopodis
17:05-17:15	Discussion	
17:15-17:35	Coffee Break	
17:35-18:45	Lecture session (III)	
17:35-18:05	BRCA1 & 2 as biomarkers in Breast & Ovarian Cancer	V. Ramfidis
18:05-18:35	Emerging biomarkers in prostate cancer	F. Koinis
18:35-18:45	Discussion	



18:45-20:00 Session 4: Circulating tumor DNA

18:45-19:05	Definition and methods of detection of DNA mutations in the plasma	E. Tzanikou
19:05-19:25	Correlation of ctDNA to tumor biopsy and clinical relevance	F. Papageorgiou
19:25-19:45	Quality assurance on the ctDNA analysis in the clinic	E. Lianidou
19:45-20:00	Discussion	
20:00-20:30	Lecture session (IV)	
20:00-20:30	Comprehensive Genomic Profiling in the era of personalized healthcare	I. Athanasiadis

Friday October 20th, 2017

09:00-10:15 Session 5: CTCs Biology

09:00-09:20	Gene mutations in CTCs	A. Voutsina
09:20-09:40	Dormancy status of Circulating Tumor Cells in various tumor types	I. Messaritakis
09:40-10:00	The molecular signature of stemness and EMT in liquid tissues	A. Strati
10:00-10:15	Discussion	

10:15-11:35 Session 6: Clinical relevance of liquid biomarkers in Breast Cancer

10:15-10:35	Clinical value of CTCs in early Breast Cancer	V. Georgoulias
10:35-10:55	Clinical value of CTCs in metastatic Breast Cancer	N. Xenidis
10:55-11:15	Novel promising liquid biomarkers in breast cancer based on ctDNA, mRNA, miRNA, DNA mutations and DNA-methylation analysis	E. Lianidou
11:15-11:35	Discussion	
11:35-12:00	Coffee Break	

12:00-13:20 Session 7: Clinical Relevance of Biomarkers in Lung Cancer

12:00-12:20	Clinical value of CTCs in NSCLC and SCLC	I. Messaritakis
12:20-12:40	ctDNA: its role in tumor molecular characterization and monitoring of the treatment efficacy in NSCLC	

12:40-13:00	Veristrat testing	A. Markou
13:00-13:20	Discussion	I.P. Katsaounis

13:20-15:10 Lecture session (V)

13:20-13:50	DNA damage and mutational load as biomarker in immunotherapy	A. Klinakis
13:50-14:20	Liquid Biopsies and companion diagnostics	E. Prinarakis
14:20-14:50	Wrap up, panel discussion and closing remarks	
14:50-15:10	Discussion	
15:10-15:20	Closing Remarks	



Scientific | Cultural Events and Publications T +30 210 7240608 F +30 210 7240139 E info@scep.gr www.scep.gr